Editor - Ken H. Young | University of Texas | 24796

Immunology: Current Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Ken H. Young

Ken H. Young
Ken H. Young
University of Texas
University of Texas


University of TexasKen H. Young, MD PhD is an Associate Professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. He was Medical Director of Hematology at the University of Wisconsin School of Medicine and University East & West Clinic Laboratories, overseeing the laboratories at the University of Wisconin Hospital and Clinics Core Laboratory. He received his PhD from University of Lund School of Medicine and completed his MD training from Oregon Health Science University. He is board certified in Anatomic and Clinical Pathology and Hematopathology.

Education focused lectures in American Society of Pathology and Hematology:

1. Acute myelogenous leukemia - WHO classification and clinical issues

2. Peripheral T-cell lymphoma - Current WHO classification and new challenge

3. New WHO Classification of Lymphoid Neoplasms

4. Dendritic and Histiocytic Neoplasms - New WHO Classification and clinical issues

5. Myelodysplastic Syndrome - WHO Classification and new challenge

6. Automated Hematology Analysis

7. Molecular Diagnostics and Cytogenetics in Lymphoma and Leukemia Applications

8. Hodgkin lymphoma - Diagnosis, Differential Diagnosis and Molecular Mechanism

9. Bone Marrow and Peripheral Blood Pathology (AACLS lecture award)

10. Flow cytometry and its application in hematologic malignancies

11. Lymphoid Neoplasms – Where we stand now for the standard care in the molecular century

12. Molecular mechanisms of DLBCL – what relevant to the clinical management

13. EBV+ Lymphoma: Biology, Mechanism and Clinical Management

Research Interest

His interests are to characterize molecular defects in patients with leukemia and lymphoma by using gene expression profiling, immunophenotypic method, methylation-microRNA-CGH arrays and current NGS molecular technologies with particular interest in tumor suppressor genes, oncogenes, p53 and NF-kB pathways. He has worked extensively on molecular diagnostics for human cancer and has obtained several novel discoveries valuable to predict treatment response, clinical outcome and survival in cancer patients.